How Biosimilars Follow Their Own Sales Path, in Three Case Studies

Posted by Judith Kulich on Tue, Jan 27, 2015

Here’s a problem that pharma and biotech executives (and we at ZS) are trying hard to solve: When it comes to biosimilars—the biotech drugs rated equivalent to biologic innovators—what will convince physicians, patients and payers to switch?


>
Read More